Hyperlipidaemia News

  • 10 July 2019
    In 2012, there was the first clinical evidence of dramatic reductions in LDL cholesterol by inhibiting PCSK9 with the monoclonal antibodies (mAbs) evolocumab and alirocumab. This was followed in 2017 and 2018 with definitive proof from major cardiovascular outcome trials, FOURIER and ODYSSEY OUTCOMES, that PCSK9 mAb therapy reduces cardiovascular...
  • 31 May 2019
    Familial hypercholesterolaemia (FH, inherited high cholesterol) is one of the commonest inherited diseases in the world with an estimated frequency of 1:200 to 1:250 for Caucasian populations1. In South Africa, the prevalence in certain population groups such as the Afrikaner, Jewish and south-Asian Indians is as high as 1:80, probably due to a...
  • 31 May 2019
    From Spain Data from Spain shows that the PCSK9 inhibitor evolocumab is mainly prescribed to patients with familial hypercholesterolaemia (FH, inherited high cholesterol and/or clinical atherosclerotic disease, according to this report.1 In Spain, hypercholesterolaemia is mainly managed at internal medical units, focusing on patients with very...
  • 30 May 2019
    Inclisiran (an siRNA therapeutic targeting PCSK9) showed promise in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the proof-of-concept ORION-2 trial.1 Results were reported at the first late breaking session of the EAS Congress in Maastricht by lead investigator, Professor Derick Raal (University of...
  • 30 May 2019
    EAS Congress also reported news for LIB003, a recombinant fusion protein therapeutic agent consisting of a PCSK9-binding domain (adnectin) and human serum albumin. In high risk patients with hypercholesterolaemia, LIB003 reduced LDL cholesterol by more than 70% in this 12-week trial.1 Compared with the PCSK9 monoclonal antibodies, targeting...
  • 30 May 2019
    Analysis of more than 1.7 million patient records in the UK Clinical Practice Research Datalink database, showed that many patients with likely familial hypercholesterolaemia (FH, inherited high cholesterol) are not diagnosed. This is important as these individuals are twice as likely to die prematurely – before the age of 55 years in men or 60...
  • 08 May 2019
    Trial VESALIUS-CV (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke) ClinicalTrials.gov Identifier: NCT03872401 Aim To investigate the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial...
  • 08 May 2019
    Amgen has announced a new cardiovascular outcomes study in patients at high risk of cardiovascular event who are already receiving lipid lowering treatment but have not had a previous myocardial infarction (MI) or stroke. VESALIUS-CV is a multinational, double-blind, randomised, placebo-controlled, parallel-group clinical outcomes study which...
  • 08 May 2019
    Based on data from ODYSSEY OUTCOMES (1), the Food and Drugs Administration has now approved alirocumab to prevent heart attack, stroke and unstable angina requiring hospitalization. ODYSSEY OUTCOMES, the longest cardiovascular outcomes trial of any PCSK9 inhibitor to date, assessed the effect of alirocumab on the occurrence of major adverse...
  • 30 April 2019
    The size of the population in China implies a major burden of familial hypercholesterolaemia (FH, inherited high cholesterol). Yet, like the majority of countries world-wide, FH is underdiagnosed and undertreated. China may pose specific issues that contribute to this. Cholesterol levels have been lower in China than in Western countries, mostly...
  • 30 April 2019
    Treatment with evolocumab, in addition to standard of care including statin therapy, was well tolerated and led to sustained reduction in LDL cholesterol in Japanese subjects enrolled in the long-term OSLER studies (Open-Label Study of Long-Term Evaluation Against LDL-C). The OSLER studies were designed to evaluate the long-term efficacy and...
  • 30 April 2019
    PCSK9 inhibitors have been endorsed for use in patients at high and very risk of cardiovascular events (1,2). In the real-world, however, which type of patients are more commonly prescribed a PCSK9 inhibitor? Findings based on data from three Danish registries indicate that the majority are those with established ischaemic heart disease who are...
  • 30 April 2019
    PCSK9 inhibitors are highly efficacious LDL cholesterol lowering treatments that have been endorsed by guidelines and experts for use in very high-risk patients (1-3). The key groups identified by these groups have been patients with clinical atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolaemia (FH, inherited high...
  • 26 April 2019
    Results from the BANTING study add to the evidence-base that PCSK9 inhibition is efficacious in improving lipid goal attainment in individuals with type 2 diabetes mellitus (T2DM) with hypercholesterolaemia or mixed dyslipidaemia. There were also favourable changes in postprandial lipids. Dyslipidaemia is one of the key risk factors for...
  • 16 April 2019
    The European Union (EU) has now approved alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) monoclonal antibody, to reduce the risk of cardiovascular events in patients with established cardiovascular disease.1 The approval is based on data from the ODYSSEY OUTCOMES trial, which not only showed significant reduction in major...
  • 20 March 2019
    In a clinical late breaking session, this year’s Congress highlighted a subgroup analysis from ODYSSEY OUTCOMES, focusing on the role of elevated lipoprotein(a) [Lp(a)] as a contributor to cardiovascular event reduction with alirocumab.1 To recap, ODYSSEY OUTCOMES compared the safety and efficacy of the PCSK9 inhibitor alirocumab with placebo...
  • 20 March 2019
    Why clinicians need to consider polyvascular disease Another analysis from ODYSSEY OUTCOMES focused on patients with atherosclerosis evident in more than one vascular bed. Patients were categorized according to the presence of polyvascular disease in two beds (coronary and peripheral artery or cerebrovascular disease, n= 1,405), vascular disease...
  • 20 March 2019
    Lp(a) and plaque Patients with higher Lp(a) levels had more atherosclerotic plaque, especially with concomitant elevated LDL cholesterol levels, according to this analysis from Japan. In total, 255 consecutive patients with stable coronary artery disease underwent optical coherence tomography imaging of culprit lesions. The prevalence of thin-cap...
  • 12 February 2019
    PCSK9 Forum Professor John Chapman (Pitié-Salpétrière University Hospital, and Sorbonne University, Paris, France) discusses how OMICS technologies could provide a precision medicine approach to managing non-LDL lipids. As a causal factor in atherosclerotic cardiovascular disease (ASCVD), measurement of LDL cholesterol has facilitated enormous...
  • 12 February 2019
    A new analysis from the ORION-1 trial shows that the efficacy and safety of inclisiran, a small interfering RNA (siRNA) therapeutic, is not influenced by diabetes status. Inclisiran differs from monoclonal antibody therapy by acting intracellularly in the liver to inhibit synthesis of PCSK9 protein in hepatocytes, thereby reducing LDL-receptor...

Pages